SecBot SecBot

ARTL

ARTELO BIOSCIENCES, INC.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001621221 Biotech & Drug Discovery
$2.20 −0.35 (−13.73%)
Oct 26 4:00 PM ET · prev $2.55
Market cap
$1.4M
Nano cap
Next earnings
Nov 10
in 14 days
1 year
−97.6%
from $90.99 · Oct 27
30 days
−48.8%
from $4.30
52-week range
$2.20–95.85
at the low
Avg volume 20D
47.3K
Oct 26 spike 169.4K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 1 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 10, 2026
Strongest BEARISH Artelo Biosciences disclosed that it was among ~180 Nasdaq-listed companies initially identified as having a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • TrendDOWNTREND

    52% below its 50-day average. New closing low $2.20 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCDOUBLED66,341$74.3K
Pacer Advisors, Inc.ADD445,544$418.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Nov 2025
Recent actions
DateFirmActionRating
Nov 19, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Sep 8, 2025D. Boral Capital
DOWNGRADE
DOWNGRADEHold
Aug 26, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Aug 18, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Aug 6, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Aug 4, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
ARTL Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Sep 23, 2026
Trading halt
Halt Resumed: ARTL — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-23T17:11:37.000Z | Resumed 2026-09-23T17:21:37.000Z
Sep 23, 2026
Trading halt
Trading Halt: ARTL — LUDP (Volatility Trading Pause)
Artelo Biosciences, Inc. CS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 23, 2026
Trading halt
Halt Resumed: ARTL — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-23T16:59:39.000Z | Resumed 2026-09-23T17:09:39.000Z
Sep 23, 2026
Trading halt
Trading Halt: ARTL — LUDP (Volatility Trading Pause)
Artelo Biosciences, Inc. CS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

Insider ledger

Form 4
🔒 Subscribers only
6 transactions
DateInsiderTypeValue
Jul 17, 2026🔒 Fresh data, subscribers onlyAWARD
Jul 17, 2026🔒 Fresh data, subscribers onlyAWARD
Jul 17, 2026🔒 Fresh data, subscribers onlyAWARD
Jul 17, 2026🔒 Fresh data, subscribers onlyAWARD
Jul 17, 2026🔒 Fresh data, subscribers onlyAWARD
Jul 17, 2026🔒 Fresh data, subscribers onlyAWARD

Earnings setup

Estimates
Nov 10
reports in 14 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Reddit

Fresh Reddit data

The last 24 hours of Reddit activity are for subscribers.

Subscribe for Full Access
Recent comments
r/wallstreetbets10h ago
Fresh comment, for subscribers
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 23, 2026Volatility PauseResumed
Sep 23, 2026Volatility PauseResumed
Sep 23, 2026Volatility PauseResumed
Sep 23, 2026Volatility PauseResumed
Sep 23, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Other
🔒 Fresh data, subscribers only
Oct 9, 2026 SEC
Artelo Biosciences disclosed that it was among ~180 Nasdaq-listed companies initially identified as having a market…
8-K — Impact 5/10
Sep 16, 2026 Press
Artelo Biosciences announced nonclinical results showing its oral dual cannabinoid agonist ART27.13 produced ~20%…
Impact 6/10
Aug 13, 2026 SEC
Artelo Biosciences reported Q2 2026 net loss of $2.4M ($0.89/share) vs $3.2M in Q2 2025, with R&D expenses halved to…
PRESS-RELEASE — Impact 4/10
Jul 17, 2026 Insider
🔒 Fresh data, subscribers only
Jul 17, 2026 Insider
🔒 Fresh data, subscribers only
Jul 17, 2026 Insider
🔒 Fresh data, subscribers only
Jul 16, 2026 SEC
No summary provided
DEFA14A — Impact 5/10

SecBot reports

16 filings · 7 press releases · 0 bullish · 9 bearish · 1 mixed · 6 neutral
All ARTL filing & press-release reports (23)